- Indivior said Tuesday the trial of its opioid addiction treatment met its primary and key secondary endpoints demonstrating 'clinically and statistically' significant differences in percentage abstinence from opioid use.

Findings from the trial showed both the 300/300 mg and 300/100 mg dosage regimens of the company's opioid addiction Sublocade delivered 'sustained buprenorphine exposure for the entire monthly period while increasing abstinence rates and controlling craving and withdrawal symptoms for patients compared to placebo,' Christian Heidbreder, Ph.D., Chief Scientific Officer of Indivior.

'This represents an effective option in the treatment of opioid use disorder,' said Christian Heidbreder, Ph.D.

The results from the 24-week clinical trial were published by The Lancet.

At 9:19am: [LON:INDV] Indivior Plc share price was -4.37p at 113.93p

Story provided by